Siemens opens molecular diagnostic lab for breast cancer research
Siemens Healthcare has established new research laboratories for molecular diagnostics in Cologne, Germany, to focus on breast cancer research.

The company said that almost 40 of its employees have been developing new diagnostic tests to help the treating physician find an individually optimized therapy for as many patients as possible, thus combining better chances of recovery with reduced side effects.

Also, Siemens said it has been researching biochips to enable clinics to perform newly developed breast cancer tests.

The 40 Cologne employees have been developing innovative diagnostic tests which can be used to precisely describe the molecular characteristics of a patient's tumor cells, the company said.